Comparative Pharmacology
Head-to-head clinical analysis: EQUANIL versus SONATA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EQUANIL versus SONATA.
EQUANIL vs SONATA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gamma-aminobutyric acid (GABA) receptor positive allosteric modulator; increases frequency of chloride channel opening, potentiating inhibitory neurotransmission.
Zaleplon is a non-benzodiazepine hypnotic that selectively binds to the benzodiazepine type 1 (BZ1) receptor subtype on the gamma-aminobutyric acid (GABA) A receptor complex, potentiating GABA-mediated chloride ion influx and neuronal inhibition.
400 mg orally 3-4 times daily; maximum 2400 mg/day. Alternatively, 200 mg orally 3-4 times daily for mild anxiety.
10 mg orally at bedtime; range 5-20 mg; maximum 20 mg per day.
None Documented
None Documented
Terminal elimination half-life is 6-20 hours (mean 10 hours). In hepatic cirrhosis, half-life may be prolonged to 24-36 hours due to impaired clearance.
Terminal elimination half-life is approximately 1 hour (range 0.7–1.7 h) in healthy adults; elderly patients and those with hepatic impairment may have prolonged half-life (up to 2–3 h).
Primarily renal excretion of conjugated metabolites (inactive); approximately 90% of a dose is excreted in urine, with less than 10% in feces. Less than 5% is excreted unchanged.
Approximately 83% of administered radioactivity is excreted in urine (with less than 1% as unchanged drug) and 17% in feces.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic